Bit Bio Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Bit Bio's estimated annual revenue is currently $38.6M per year.(i)
  • Bit Bio's estimated revenue per employee is $155,000

Employee Data

  • Bit Bio has 249 Employees.(i)
  • Bit Bio grew their employee count by 7% last year.

Bit Bio's People

Founder & CEOReveal Email/Phone
Co-FounderReveal Email/Phone
Head Computational Genomics Non-ClinicalReveal Email/Phone
SVP BD & Cell Therapy PartnershipsReveal Email/Phone
VP, Programme Management OfficeReveal Email/Phone
VP, Portfolio Strategy and Business OperationsReveal Email/Phone
VP Research and DevelopmentReveal Email/Phone
VP FinanceReveal Email/Phone
VP Cell Therapy Program LeaderReveal Email/Phone
VP Translational Medicine, ImmunologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Bit Bio?

Bit Bio is an award-winning human synthetic biology enterprise. Our mission is to code cells to advance the wellbeing of humanity. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy. Collaboration is at the heart of Bit Bio. We are empirical, highly ambitious and driven by a common purpose.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Bit Bio News

2022-04-20 - IPL 2022: RCB organize Glenn Maxwell’s wedding party in bio-bubble, Virat Kohli shakes a leg

Owing to his wedding, Maxwell entered the RCB bio-bubble a bit late and also missed a few games. In any case, he wouldn't have played before...

2021-11-08 - secures $103M has raised a $103 million Series B from investors including Arch Ventures, Foresite Capital and Charles River Laboratories. Based in San Francisco and the UK, the company is a developer of cell coding technology intended to discover new cell therapies. View round

2021-11-08 - U.K.-based secures €89.1M to expedite gene engineering technology to fight diseases

Cambridge, UK-based, a human cell coding company, raised $103M (approx €89.1M) in a Series B round of funding. Arch Ventures, Charles River Laboratories, Foresite Capital, Resilience, Metaplanet, Puhua Capital, and Tencent participated in the funding round.A new, prominent Board of Direc ...

2021-11-05 - raises $103 million in first close of Series B financing raises $103 million in first close of Series B financing 05-11-2021 Today announces the first close of its Series B financing of $103 million. The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM. New and e ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding